Načítá se...
Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab (Cosentyx(®)), a first-in-class fully human monoclonal antibody against interleukin-17A, is approved in several countries, including the USA and those of the EU, for the treatment of ankylosing spondylitis (AS). Subcutaneous secukinumab significantly improved the clinical signs and sympt...
Uloženo v:
| Vydáno v: | Drugs |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer International Publishing
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6422944/ https://ncbi.nlm.nih.gov/pubmed/30793255 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-019-01075-3 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|